Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim Cramer

CNBC's Jim Cramer and the 'Squawk on the Street' team discuss shares of Eli Lilly after the U.S. Food and Drug Administration granted the company a fast-track designation for its obesity drug.